Correlation between BCR-ABL Expression and Tumor Burden is Restricted to the Transition from Minor to Major Cytogenetic Response in Interferon Treated CML Patients

"A pre-Gleevec study"

L. Kereskai, János A. Vass, Mária Kneif, László Pajor

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The interferon treatment of chronic myeloid leukaemia has been monitored by investigating the tumour burden as revealed by fluorescence in situ hybridization and the expression of BCR-ABL chimera determined by quantitative reverse transcription polymerase chain reaction. These parameters were obtained from the peripheral blood of 51 untreated and 104 follow-up patient samples. Poor corrrelation (r = .31) was found between BCR-ABL expression and tumor load in all samples as well as in untreated patients, and this correlation was even less in all follow-up cases (r = .28). Regarding chimera expression five order of magnitude difference existed in the untreated patients and this value dropped to two in those with complete cytogenetic response. Only the major and the complete cytogenetic response groups differed significantly (p .001) in the BCR-ABL expression from that of patients at diagnosis. Among the different cytogenetic response groups the only significant difference (p

Original languageEnglish
Pages (from-to)174-179
Number of pages6
JournalPathology and Oncology Research
Volume9
Issue number3
Publication statusPublished - 2003

Fingerprint

Tumor Burden
Cytogenetics
Interferons
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Fluorescence In Situ Hybridization
Reverse Transcription
Polymerase Chain Reaction
Imatinib Mesylate
Therapeutics

Keywords

  • Chronic myeloid leukaemia
  • Fluorescence in situ hybridisation
  • Molecular monitoring
  • Quantitative polymerase chain reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{85cb9bc69efb42268e928ef7d9130b84,
title = "Correlation between BCR-ABL Expression and Tumor Burden is Restricted to the Transition from Minor to Major Cytogenetic Response in Interferon Treated CML Patients: {"}A pre-Gleevec study{"}",
abstract = "The interferon treatment of chronic myeloid leukaemia has been monitored by investigating the tumour burden as revealed by fluorescence in situ hybridization and the expression of BCR-ABL chimera determined by quantitative reverse transcription polymerase chain reaction. These parameters were obtained from the peripheral blood of 51 untreated and 104 follow-up patient samples. Poor corrrelation (r = .31) was found between BCR-ABL expression and tumor load in all samples as well as in untreated patients, and this correlation was even less in all follow-up cases (r = .28). Regarding chimera expression five order of magnitude difference existed in the untreated patients and this value dropped to two in those with complete cytogenetic response. Only the major and the complete cytogenetic response groups differed significantly (p .001) in the BCR-ABL expression from that of patients at diagnosis. Among the different cytogenetic response groups the only significant difference (p",
keywords = "Chronic myeloid leukaemia, Fluorescence in situ hybridisation, Molecular monitoring, Quantitative polymerase chain reaction",
author = "L. Kereskai and Vass, {J{\'a}nos A.} and M{\'a}ria Kneif and L{\'a}szl{\'o} Pajor",
year = "2003",
language = "English",
volume = "9",
pages = "174--179",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Correlation between BCR-ABL Expression and Tumor Burden is Restricted to the Transition from Minor to Major Cytogenetic Response in Interferon Treated CML Patients

T2 - "A pre-Gleevec study"

AU - Kereskai, L.

AU - Vass, János A.

AU - Kneif, Mária

AU - Pajor, László

PY - 2003

Y1 - 2003

N2 - The interferon treatment of chronic myeloid leukaemia has been monitored by investigating the tumour burden as revealed by fluorescence in situ hybridization and the expression of BCR-ABL chimera determined by quantitative reverse transcription polymerase chain reaction. These parameters were obtained from the peripheral blood of 51 untreated and 104 follow-up patient samples. Poor corrrelation (r = .31) was found between BCR-ABL expression and tumor load in all samples as well as in untreated patients, and this correlation was even less in all follow-up cases (r = .28). Regarding chimera expression five order of magnitude difference existed in the untreated patients and this value dropped to two in those with complete cytogenetic response. Only the major and the complete cytogenetic response groups differed significantly (p .001) in the BCR-ABL expression from that of patients at diagnosis. Among the different cytogenetic response groups the only significant difference (p

AB - The interferon treatment of chronic myeloid leukaemia has been monitored by investigating the tumour burden as revealed by fluorescence in situ hybridization and the expression of BCR-ABL chimera determined by quantitative reverse transcription polymerase chain reaction. These parameters were obtained from the peripheral blood of 51 untreated and 104 follow-up patient samples. Poor corrrelation (r = .31) was found between BCR-ABL expression and tumor load in all samples as well as in untreated patients, and this correlation was even less in all follow-up cases (r = .28). Regarding chimera expression five order of magnitude difference existed in the untreated patients and this value dropped to two in those with complete cytogenetic response. Only the major and the complete cytogenetic response groups differed significantly (p .001) in the BCR-ABL expression from that of patients at diagnosis. Among the different cytogenetic response groups the only significant difference (p

KW - Chronic myeloid leukaemia

KW - Fluorescence in situ hybridisation

KW - Molecular monitoring

KW - Quantitative polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=0242510872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242510872&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 174

EP - 179

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -